Issue 9 - Mar 2, 2018
Issue 8 - Feb 23, 2018
  • Conversation with the Cancer Letter

    His six-month “listening tour” almost over, Sharpless discusses his vision for NCI

    “The notion that cancer’s not one disease, but thousands of diseases is really starting to sink in, and the implications of that fact are being felt throughout [NCI], and it means we have to change how we do everything. I hope that the early days of the Sharpless administration will be remembered as a time when we really bought into that reality and did some things differently,” NCI Director Norman “Ned” Sharpless said in a conversation with The Cancer Letter.

  • Conversation with the Cancer Letter

    UT Health San Antonio’s link with MD Anderson goes live

    How does it work?

    The affiliation between UT Health San Antonio Cancer Center and MD Anderson Cancer Center became active on Feb. 20. “Administratively, the two institutions are distinct. Patients will be cared for by the physicians and nurses of the [San Antonio] Mays Cancer Center, but certainly the platform of the care that they’re being provided has been heavily informed and integrated with MD Anderson, based on their treatment templates and methodology,” Ruben Mesa, director of the Mays Cancer Center, said to The Cancer Letter.

  • In Brief

    • Frederick Schnell named to new post of COA medical director
    • Richard Barakat to lead Northwell Health cancer services, research
    • Denis Guttridge named director of MUSC Darby Children’s Research Institute, associate director at Hollings
  • TCCL Logo

  • Trials and Tribulations

    Diversity within Diversity: Lessons from the Latinos of South Texas

    Diversity is to be celebrated in our society as enriching our experiences, our cultures and the richness of our lives. Diversity within the context of cancer care and research has appropriately grown to include considerations of diversity of race, ethnic heritage, age, gender, and experiences.

  • Clinical Roundup

    • NEJM publishes Loxo’s larotrectinib clinical data
  • Drugs and Targets

    • FDA expands approval of Imfinzi to reduce the risk of NSCLC progressing
  • NCI Protocols

    NCI trials for February

    NCI approved the following clinical research studies last month.

Issue 7 - Feb 16, 2018
  • A confusing Valentine: White House proposes cutting NIH by 27 percent, and—at the same time—reverses the cut

    What a difference a week makes.

    Last week, advocates for biomedical research were bracing for another shutdown of the federal government and fearing that the president’s budget proposal for fiscal year 2019 would drastically slash NIH.

  • NCI Director’s Report

    Sharpless: NCI should increase funding for RPG pool to maintain success rates for R01s

    NCI may need to invest at least $125 million in new money in the Research Project Grant pool in 2018 if the institute plans on keeping the success rates for R01s comparable to 2017, said NCI Director Ned Sharpless.

  • In Brief

    • NCI’s Lowy and Schiller win Szent-Györgyi Prize
    • Aldape starts as chief of laboratory of pathology at the NCI
    • Aghajanian appointed as NRG Oncology Gynecologic Cancer Committee Chair
    • Hudson named co-chair of NRG Oncology Delivery Research Committee
    • AACR’s Cancer Today magazine launches new website

     

  • Funding Opportunities

    American Cancer Society Supports Early Career Clinicians’ Move into Clinical Science

    The American Cancer Society started a grant program to support early career clinicians aiming to become clinician scientists.

  • TCCL Logo

  • Trials and Tribulations

    A Cancer Patient’s War on Cancer

    Imagine a hospital ward 100 years from now. Will multi-drug resistant infections be as prominent as they are today? I suspect so, because as antibiotics evolve, so will the infectious diseases they target. It’s an arms race in which both sides have a capacity to learn and adapt. Not so cancer. Cancers can’t learn from each other. But cancer patients can. This profound imbalance in the capacity for learning is an advantage that all cancer patients share. It is our super power. And we barely use it.

  • Clinical Roundup

    • NCCN & ASCO provide joint guidance on side effects from checkpoint inhibitors
    • Phase II trial shows durvalumab active in recurrent or metastatic head and neck cancer
    • UW Carbone study finds caregiver spouses of cancer patients suffer untreated depression
  • Drugs and Targets

    • FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint
    • Roche to acquire Flatiron Health for $1.9 billion
    • BMS, Nektar form collaboration for CD122-biased agonist
    • Tivozanib gets NICE nod for first-line treatment of advanced RCC